Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar;83(4):359-365.
doi: 10.1007/s40265-023-01851-2.

Lecanemab: First Approval

Sheridan M Hoy  1
Affiliations
Review

Lecanemab: First Approval

Sheridan M Hoy. Drugs. 2023 Mar.

Abstract

Lecanemab (lecanemab-irmb; LEQEMBI™) is a humanized immunoglobulin gamma 1 (IgG1) against aggregated soluble and insoluble forms of amyloid-β peptide. It is being developed by Eisai, under a global licence from BioArctic (formerly BioArctic Neuroscience), and in collaboration with Biogen, for the treatment of Alzheimer's disease, and received its first approval for this indication on 6 January 2023 in the USA under the Accelerated Approval Pathway. According to the US prescribing information, treatment should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, and a confirmed presence of amyloid beta pathology (i.e. the population in which treatment was initiated in clinical trials). There are no effectiveness or safety data on initiating treatment at earlier or later stages of the disease than were studied. Lecanemab is undergoing regulatory review in the EU, Japan and China, with clinical development underway in several other countries worldwide. This article summarizes the milestones in the development of lecanemab leading to this first approval for the treatment of Alzheimer's disease.

PubMed Disclaimer

References

    1. Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet. 2021;397(10284):1577–90. - DOI - PubMed - PMC
    1. Knopman DS, Amieva H, Petersen RC, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7(1):33. - DOI - PubMed - PMC
    1. US FDA. FDA grants accelerated approval for Alzheimer’s disease treatment [media release]; 6 Jan 2023. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerat... .
    1. Dhillon S. Aducanumab: first approval. Drugs. 2021;81(12):1437–43. - DOI - PubMed
    1. Eisai Inc. LEQEMBI™ (lecanemab-irmb) injection, for intravenous use: US prescribing information; 2023. https://www.fda.gov/ . Accessed 10 Jan 2023.

LinkOut - more resources